Vericel Corp
NASDAQ:VCEL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
32.52
59.11
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Vericel Corp
Vericel Corp
Stock-Based Compensation
Vericel Corp
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vericel Corp
NASDAQ:VCEL
|
Stock-Based Compensation
$35.5m
|
CAGR 3-Years
6%
|
CAGR 5-Years
25%
|
CAGR 10-Years
42%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Stock-Based Compensation
$872m
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
14%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Stock-Based Compensation
$739.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
16%
|
CAGR 10-Years
17%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vericel Corp
Glance View
Vericel Corporation, nestled in the bustling hub of biomedical innovation in Cambridge, Massachusetts, has carved out a niche in the realm of advanced cell therapies. Founded in the late 1980s, the company initially focused on regenerative medicine but has since honed its expertise on the development and commercialization of cell-based treatments for patients with serious medical conditions. Vericel's journey is underpinned by its flagship product lines like MACI® and Epicel®, which illustrate its commitment to technological advancement and improving patient outcomes. MACI®, a matrix-applied autologous cultured chondrocyte technology, is designed to repair cartilage defects in the knee, often providing relief to those who suffer chronic pain from cartilage injuries. Epicel®, on the other hand, caters to patients with severe burns, utilizing a patient's own skin cells to regenerate skin and improve healing. These innovative solutions demonstrate Vericel's strategic pivot towards addressing niche, high-need areas within the orthopedic and burn treatment spaces. Vericel makes its revenue primarily through the sales of its proprietary treatments to hospitals and healthcare providers. The company's growth is closely tied to its ability to navigate the intricate regulatory landscapes associated with biologics, ensuring that its therapies meet the stringent requirements set forth by entities like the FDA. By targeting specific, high-impact markets with limited existing solutions, Vericel secures a competitive edge and commands significant pricing power, which enhances its financial performance. The company invests heavily in clinical trials and research to support and expand the use of its technologies, seeking indications for broader patient populations. Additionally, Vericel is continually working to optimize its manufacturing processes to scale its operations effectively without compromising the quality and efficacy of its treatments. Through strategic partnerships and a focus on innovation, Vericel is poised to leverage its scientific expertise to further entrench its position within the specialized markets it serves.
See Also
What is Vericel Corp's Stock-Based Compensation?
Stock-Based Compensation
35.5m
USD
Based on the financial report for Sep 30, 2024, Vericel Corp's Stock-Based Compensation amounts to 35.5m USD.
What is Vericel Corp's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
42%
Over the last year, the Stock-Based Compensation growth was 7%. The average annual Stock-Based Compensation growth rates for Vericel Corp have been 6% over the past three years , 25% over the past five years , and 42% over the past ten years .
You don't have any saved screeners yet
